RIGL catalyst calendar

RIGEL PHARMACEUTICALS INC

Upcoming catalysts
4
Cash runway
Cash generating
Cash & investments
$95M
Phase 3 programs
4

RIGEL PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on December 20, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

RIGEL PHARMACEUTICALS INC generates cash from operations, so a burn-based runway figure does not apply.

Across 22 concluded trials, 86% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 20, 2026 est. Next quarterly earnings (projected) Earnings —
April 30, 2027 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Trial Milestone Phase 4
July 30, 2027 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Trial Milestone Phase 4
June 15, 2029 Study of Olutasidenib and Temozolomide in HGG Trial Milestone Phase 2

Track RIGL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open RIGL in the tracker

Recent history

DateEventTypePhase
August 15, 2026 Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Trial Milestone Phase 1/Phase 2
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 1, 2026 8-K filed: Leadership change Corporate —
June 17, 2026 8-K filed: Acquisition completed Corporate —
May 20, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 8-K filed: Material agreement Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
March 3, 2026 Quarterly results filed (8-K) Earnings —
February 3, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 10, 2025 8-K filed: Other event Filing —
November 4, 2025 Quarterly results filed (8-K) Earnings —
August 5, 2025 Quarterly results filed (8-K) Earnings —
May 23, 2025 8-K filed: Leadership change Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —
April 15, 2024 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Trial Milestone Phase 3
September 5, 2022 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Trial Milestone Phase 3
April 11, 2022 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA Trial Milestone Phase 3
June 2, 2020 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Trial Milestone Phase 3
December 15, 2019 A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) Trial Milestone Phase 2
March 23, 2018 Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.